Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Advantage: Is It Strong Enough To Survive Obama Reform?

This article was originally published in RPM Report

Executive Summary

Medicare Advantage programs are in the crosshairs of Obama health care reform. The new president has singled out the full-service plans reconstituted under Part D as a major source for the down payment funds for comprehensive health care reform: well over a quarter of the funds for the new system would come from cuts in government payments to Medicare Advantage programs. The situation looks bad for MA plans, but it may be early to write them off. They are strong after five good years of growth.

You may also be interested in...



Predicting Health Reform: A Quick Guide To What Will Be In-and What Won't

The health care reform debate is entering the critical phase. Here are our predictions for where the legislation will end up.

Defending the Advantages of Advantage

The Obama Administration has sunk its teeth into Medicare Advantage to fi nd cost savings in the federal budget. Pharma and biotech should align with health plans to defend the program.

With Enemies Like These: Will the Democrats Make Part D More Pharma Friendly?

The Democratic leadership rammed a major health bill through the House this summer, including some Medicare Part D fixes that read like a Big Pharma wish list. Have the industry's toughest critics gone soft?

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS080543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel